Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported its third quarter and nine-month results for the period ending September 30, 2001. The company continues to invest heavily in research and development, which is reflected in increased operating expenses. While revenues have declined year-over-year, primarily due to reduced research payments from collaborators like Procter & Gamble and the winding down of certain Amgen-Regeneron Partners projects, the company strengthened its balance sheet significantly, ending the period with substantial cash and marketable securities. The company highlighted progress in its clinical pipeline, particularly with AXOKINE for obesity, which has advanced to Phase III trials. Regeneron also successfully raised significant capital through a public offering and a private placement of convertible notes, indicating investor confidence and providing resources for future development. Despite ongoing net losses, the strategic focus on retaining commercialization rights and advancing a diverse pipeline, coupled with a robust cash position, positions the company for potential future growth.
Key Highlights
- 1Strong cash and marketable securities position of $268.0 million as of September 30, 2001, bolstered by a $153.6 million net proceeds from a public offering in March 2001 and a $193.4 million net proceeds from a convertible senior subordinated notes offering in October 2001.
- 2Increased investment in Research & Development expenses, rising to $25.0 million in Q3 2001 and $61.4 million for the nine months ended September 30, 2001, indicating a commitment to pipeline development.
- 3AXOKINE® for obesity has advanced to a Phase III clinical program initiated in July 2001, with preliminary Phase II results showing meaningful weight loss and sustained results in follow-up studies.
- 4Revenue decreased year-over-year for both the three and nine-month periods, primarily due to reduced contract research and development revenue and research progress payments from key partners.
- 5Net loss for the nine months ended September 30, 2001, was $47.8 million, compared to a net loss of $14.8 million for the same period in 2000, reflecting increased R&D spending.
- 6The company is actively pursuing multiple product candidates across various therapeutic areas, including IL-1 Trap for rheumatoid arthritis and VEGF Trap for cancer, with several expected to enter Phase I trials in early 2002.
- 7Discontinuation of clinical development for BDNF by Amgen-Regeneron Partners and reduced activity in NT-3 studies impacted revenues from that collaboration.